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Background: Several observational studies suggest that therapy with inhaled
corticosteroids (ICS) is associated with reduced mortality in patients with chronic
obstructive pulmonary disease (COPD). However, none of these has reported survival
data in COPD patients with respiratory insufficiency who require domiciliary oxygen
therapy. The present study was conducted to examine the association between ICS
and all-cause mortality in patients with severe COPD and chronic hypoxemia.
Patients and methods: From a tertiary referral clinic, we identified 145 consecutive
COPD patients who met the criteria for long-term oxygen therapy between 1996 and
2002. We compared the hazard ratio (HR) for all-cause mortality over 1 year
between patients who were (n ¼ 55) and were not treated with ICS (n ¼ 90).
Results: In a crude analysis, the use of ICS was associated with a HR of 0.38 (95%
confidence interval (CI) ¼ 0.18–0.79). After adjustments for age, sex, use of oral
steroids, and b2-agonists, PaO2 and PaCO2, the HR was 0.46 (95% CI ¼ 0.21–0.98).
Conclusions: Our findings indicate that ICS may reduce all-cause mortality in
patients with severe COPD and chronic hypoxemia, who require long-termElsevier Ltd. All rights reserved.
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R. Tkacova et al.386domiciliary oxygen therapy. These data suggest that ICS may play an important role
in improving clinical outcomes in patients with advanced COPD.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality, and is
the only major disease in the developed countries
for which mortality is increasing.1 Because of the
inflammatory nature of COPD, corticosteroids
may have a beneficial effect in COPD and many
practising clinicians use inhaled corticosteroids
(ICS) for symptomatic treatment of COPD patients.
There is, however, no consensus on the effective-
ness of ICS on hard clinical outcomes such as
mortality.2 Up to now, there have been no
published clinical trials that have evaluated
the effects of ICS on mortality as the primary
outcome and as such the effects of chronic ICS
therapy on all-cause mortality remain uncertain.2
Several,3–5 but not all6,7 large population-
based observational studies have shown that
therapy with ICS is associated with reduced
hospitalization and mortality rates in patients
with COPD. Some of the inconsistencies in the
results across these studies may relate to differ-
ences in methodologic design and immortal time
bias.8 However, a recent study by Kiri et al.9
demonstrated a survival effect with ICS even when
immortal time bias and other methodologic issues
were accounted for, providing support for a true
association.
Many of the previous observational studies have
evaluated the relationship between ICS and survival
using administrative data and, as such, could not
account for salient physiologic data such as forced
expiratory volume in 1 s (FEV1) or arterial blood
gases in their analyses.3–5 Moreover, none of the
studies has focused on those with very severe
disease, who are at a high risk for mortality. For
exacerbations and patient symptoms, ICS are most
effective when given to patients with moderate-to-
severe COPD. They do not appear to be very
effective in those with mild disease.10 If this
construct also applies to survival, ICS may be highly
effective in reducing mortality in patients with
severe COPD, who require domiciliary oxygen
therapy since such patients have poor prognosis.
None of the studies to date has evaluated the
effects of ICS on survival in this patient popula-
tion.11 The aim of the present study was to examine
the association between ICS treatment and all-
cause mortality over a 1-year period in patients
with severe COPD, who also demonstrate chronicrespiratory insufficiency meeting the indication
criteria for long-term oxygen therapy (LTOT).Patients and methods
Patients
The study subjects were recruited consecutively in
a university hospital setting between the years
1996 and 2002. The inclusion criteria were: (a) a
documented outpatient clinic visit or an inpatient
hospitalization with a primary diagnosis of COPD;
(b) use of at least one bronchodilator medication
before the index visit or hospitalization date; (c)
chronic respiratory insufficiency meeting the in-
dication criteria for LTOT; (d) LTOT prescription,
compliance with O2 therapy and abstention from
smoking; and (e) stable condition at the time of
LTOT initiation. Exclusion criteria were: (a) indica-
tion for LTOT for conditions other than COPD (e.g.
primary and secondary interstitial lung diseases,
chronic persistent asthma, chest deformities,
chronic sequelae of tuberculosis), or (b) non-
compliance with the requirements for continued
O2 therapy, i.e. persistence in smoking and/or
refusal to use LTOT for at least 16 h daily.
Data on patient characteristics, medication used,
blood gases, as well as biochemical and ventilo-
metric data were abstracted from a special chart
that was completed by the LTOT prescribing
physician at the time of LTOT initiation. Informa-
tion regarding survival was retrieved from charts of
home oxygen vendors, who were mandated to
capture the date of death as well as the date when
the O2 concentrator was returned to the company
for all decedents enrolled in the LTOT program. No
patients were lost to follow-up.
Pulmonary function tests and biochemical
analyses
Pulmonary function tests were evaluated with the
use of body plethysmography (Jaeger, Germany).
All pulmonary function testing was performed
according to the European Respiratory Society
standards with the patients in a sitting position.
Pulmonary function measurements were per-
formed at the same time of the day under the
same body temperature and pressure standard
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ensure consistency of the technique. Three tech-
nically acceptable measurements were performed
on each patient, and the highest value was included
in the analyses. Arterial blood samples were
obtained by puncture of the radial artery with the
patient seated. Blood (5mL) for biochemical
analyses was withdrawn by venepuncture. Bio-
chemical analyses were performed using standard
techniques.Table 1 Primary causes of chronic respiratory
insufficiency in a cohort of 190 patients.
Diagnosis Number of
patients
Chronic obstructive pulmonary disease 145
Idiopathic pulmonary fibrosis 22
Fibrosis resulting from tuberculosis 6
Bronchial asthma 7
Kyphoscoliosis 6
Bronchiolitis obliterans 2
Cystic fibrosis 1
Alveolar lipoproteinosis 1Statistical analysis
All data on medications were obtained at the time
of LTOT initiation. Categorization of ICS user and
non-user status was done based on whether
patients were or were not receiving ICS at the
time of LTOT initiation. The decision to start ICS
therapy was left to the attending physician, who
had initially referred the patients to the Depart-
ment for determination of long-term domiciliary
oxygen therapy. Thus, ICS status was determined at
the beginning of person-time follow-up. Unlike
previous studies by Sin and Tu3 and by Soriano et
al.4 we did not use a window of time to define
exposure, thus avoiding immortal time bias. We
used a time-fixed model to compare the mortality
rates between ICS users and non-users. The index
date was defined as the date when patients
received domiciliary oxygen therapy for the first
time. The patients were then followed for a full
year after the index date or until the date of
their death for those who expired during the one-
year follow-up period. The crude survival curves
were constructed using the Kaplan–Meier method.
Proportional hazards assumption was tested vi-
sually and it was met. The adjusted mortality
rates of patients who did and did not receive ICS at
the time of LTOT initiation were compared using a
Cox proportional hazards model. In the adjusted
model, age, sex, Charlson comorbidity score, PaO2,
PaCO2 and prescriptions for b2-agonists and oral
corticosteroids, were included as co-variates. All
information on medication was obtained at the
time of LTOT initation and therefore reflects what
patients were receiving at the beginning of the
follow-up period. Addition of other variables (e.g.
use of other bronchodilators, arterial hyper-
tension, cardiac medications, FEV1, serum choles-
terol) made little difference to the overall results
and as such were not included in the final
model. Analyses were conducted using SAS version
8.2 (Carey, North Carolina). Continuous variables
are presented as mean7SD, unless otherwise
specified.Results
Study population
Between 1996 and 2002, 190 patients (139 men and
51 women, age 40–89 years) with chronic respira-
tory insufficiency underwent a thorough examina-
tion including detailed lung function and blood
gases analyses at the time of LTOT initiation in the
Department of Respiratory Medicine and Tubercu-
losis of the Teaching Hospital (Kosice, Slovakia).
Table 1 lists the primary causes of their chronic
respiratory insufficiency and the indications for
LTOT.
The study group consisted of 145 patients with
COPD (117 men and 28 women; mean age 67.378.9
years, range 40–89 years). Of these patients: 117
(81%) were men; 22 (15%) had no comorbid
conditions; 44 (30%) had a Charlson comorbidity
score of 1; 77 (53%) had a Charlson comorbidity
score ofX2. Coronary heart disease was present in
123 (85%) patients, and arterial hypertension was
present in 62 (43%) patients. The mean FEV1 of the
cohort was 1.0370.33 L (37.3711.5% of predicted
values), and the mean FEV1/forced vital capacity
(FVC) ratio was 46.6710.1%. The mean residual
volume (RV) was 4.671.3 L (193.6757.9% pre-
dicted), and the ratio of RV to total lung capacity
was 64.770.8%. The mean PaO2 was 6.627
0.78 kPa; the mean PaCO2 was 6.6571.31 kPa; and
the mean SaO2 was 83.376.0%. All measurements
were performed while the patient was breathing
room air. The patients had a mean hemoglobin
concentration of 150719 g/L, mean cholesterol
concentration of 4.9771.15mmoL/L and serum
albumin of 41.773.8 g/L. All patients were in
stable clinical condition at the time of LTOT
initiation as indicated by the absence of clinical
signs of an acute exacerbation, and by a normal
mean leucocyte count of 8.373.3 109/mL.
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Table 2 Pulmonary and cardiac medication at the start of long-term oxygen therapy in patients with COPD not
treated with ICS versus patients treated with ICS.
Not treated with ICS (n ¼ 90) Treated with ICS (n ¼ 55) P
Ipratropium bromide (%) 63.3 63.6 0.971
b2-agonists (%) 55.4 70.9 0.049
Expectorants (%) 30.0 32.7 0.731
Oral corticosteroids (%) 21.1 34.6 0.074
Theophyllines (%) 95.6 100.0 0.113
Digoxin (%) 65.6 56.4 0.268
b-Blocker (%) 1.1 1.8 1.000
ACE-inhibitor (%) 15.6 23.6 0.225
Diuretic (%) 66.7 58.2 0.303
ICS, inhaled corticosteroids; COPD, chronic obstructive pulmonary disease; ACE, angiotensin converting enzyme.
Table 3 Baseline characteristics and comorbid conditions in patients with COPD not treated with ICS versus
patients treated with ICS.
Not treated with ICS (n ¼ 90) Treated with ICS (n ¼ 55) P
Age (years) 68.279.0 65.878.5 0.099
Male (%) 83.3 76.4 0.302
BMI (kg/m2) 25.976.0 26.075.5 0.930
Charlson index 1.1270.6 1.3270.7 0.102
Comorbid conditions present (%) 83.3 83.6 0.348
Coronary heart disease (%) 77.5 79.6 0.768
Myocardial infarction (%) 18.0 18.5 0.935
Left ventricular failure (%) 30.3 20.8 0.212
Arterial hypertension (%) 33.3 52.8 0.023
Stroke (%) 5.6 1.9 0.409
Diabetes (%) 17.8 20.0 0.739
Right ventricular failure (%) 53.7 56.5 0.749
R. Tkacova et al.388Eighty-eight (61%) of the studied patients were
taking inhaled short-acting b2-adrenergic medica-
tions, 92 (64%) received ipratropium bromide, 38
(26%) received oral corticosteroids, and 141 (97%)
received oral theophyllines (Table 2). Additionally,
in order to treat the cardiovascular comorbidities,
90 (62%) patients were taking digoxin, 27 (19%)
angiotensin-converting enzyme inhibitors, 92 (63%)
diuretics, and 2 (1%) cardioselective b-blockers.Inhaled corticosteroid use
Fifty-five patients (38%) were taking ICS, whereas
90 patients were not. Among the patients taking
ICS, 45 patients received beclomethasone, six
received fluticasone, and four received budeso-
nide. The dose of inhaled beclomethasone ranged
from 400 to 1000 mg per day. There were no
significant differences in the age, body mass
index, gender distribution or Charlson index be-
tween those who were and were not taking ICS(Table 3). Although the proportion of patients with
coronary heart disease, previous myocardial infarc-
tion, left ventricular failure, previous stroke,
diabetes mellitus and signs of right ventricular
failure were similar between the two groups, the
proportion of patients with arterial hypertension
was slightly higher in patients taking ICS compared
with those not taking ICS (Po0:05). Pulmonary
function was similar between the two groups
(Table 4). The baseline PaO2 was lower, and the
baseline PaCO2 was higher before O2 administration
in those not taking ICS compared to patients
receiving ICS (6.570.8 versus 6.870.7 kPa,
Po0:02; 6.871.4 versus 6.471.0 kPa, Po0:05,
respectively). However, after 30min of O2 admin-
istration, no significant differences were seen in
blood gases between the two groups: PaO2 was
8.571.3 kPa in the not-ICS treated, and
8.671.3 kPa in the ICS-treated group (P ¼ NS);
PaCO2 was 6.771.8 kPa in the not-ICS treated and
6.571.2 kPa in the ICS-treated group (P ¼ NS).
The increase in PaO2 from the baseline to values
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Table 4 Pulmonary function tests at the start of long-term oxygen therapy in patients with COPD not treated
with ICS versus patients treated with ICS.
Not treated with ICS (n ¼ 90) Treated with ICS (n ¼ 55) P
FEV1 (L) 1.0670.37 0.9870.28 0.246
FEV1 (% predicted) 37.9711.8 36.2711.3 0.416
FVC (L) 2.2070.68 2.2070.66 0.939
FVC (% predicted) 62.5714.3 62.3715.6 0.936
FEV1/FVC (%) 47.5710.4 45.179.6 0.214
RV (L) 4.571.4 4.771.4 0.634
RV (% predicted) 190.7757.9 191.9758.9 0.815
TLV (L) 6.971.6 7.371.7 0.338
TLC (% predicted) 111.5721.2 114.5723.0 0.520
RV/TLC (%) 64.578.9 65.077.7 0.795
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLV, total lung volume; TLC, total lung
capacity; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.
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Figure 1 Kaplan–Meier survival curves of COPD patients
with chronic respiratory insufficiency who did and did not
use inhaled corticosteroids following the initiation of
LTOT at home. P ¼ 0:006 using log-rank statistics.
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Figure 2 Adjusted suvival curves of COPD patients with
chronic respiratory insufficiency who did and did not use
inhaled corticosteroids following the initiation of LTOP at
home. The survival curves have been adjusted for age,
sex, PaCO2, PaO2, and use of short-acting b2-agonists and
oral corticosteroids. Adjusted P-value ¼ 0.036.
Inhaled corticosteroids and survival in COPD 389after 30min of O2 administration was statistically
significant in both, the ICS-treated and in the not-
ICS group (Po0:001 and 0.001, respectively).
Survival
The overall survival was poor: only 100 (69%)
patients survived to 1 year. At one-year of follow-
up, 36 patients who were not receiving ICS and nine
patients who were treated with ICS had died. COPD
patients who were treated with ICS had signifi-
cantly greater 1-year survival (84%) than those who
did not receive ICS (60%) (log-rank statistics
Po0:05) (Fig. 1). Crudely, the use of ICS was
associated with a hazard ratio (HR) of 0.38 (95%
confidence interval, CI ¼ 0.18–0.79). After adjust-
ments for age, sex, use of oral steroids, b2-agonists,and antibiotics, PaO2 and PaCO2, the HR was 0.46
(95% CI ¼ 0.21–0.98) (Fig. 2) suggesting that those
treated with ICS were 54% less likely to die at one
year than those not treated with ICS.Discussion
By studying a well defined group of patients with
severe COPD, who also had chronic respiratory
insufficiency meeting the criteria for LTOT pre-
scription, the present study reports that ICS
therapy was associated with a 54% reduction in
the risk of all-cause mortality over 1 year. Although
previous observational studies have demonstrated
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COPD, none of the studies had evaluated this
relationship among patients with very advanced
disease. Similarly, clinical trials have generally
excluded such patients because of their general
frailty.7 Paradoxically, however, these patients
have the greatest risk of death and any therapies
that may modify survival are likely to have the
greatest salience and the largest impact in these
patients.
The current study was not a randomized con-
trolled study and as such certain limitations are
inherent. For instance, immortal time bias may be
of concern.8 However, the allocation of patients
into ICS or control category was done at the time of
LTOT initiation. The strength of this approach is
that this method precludes any possibility of
immortal time bias since there is no window of
time for exposure. The weakness is that this
method is susceptible to exposure misclassification
if patients during the one-year follow-up period
‘‘crossed-over’’ in their exposure status. In other
words, users of ICS could have become ‘‘non-users’’
during the follow-up period if they became non-
compliant with their therapy and non-users of ICS
could have later become ‘‘users’’ of ICS if their
condition worsened and their physicians decided to
treat them with ICS. We have shown previously,
however, that the magnitude of exposure misclas-
sification from ‘‘cross-over’’ of exposure status is
usually very modest over a 1-year period.12 More-
over, this type of misclassification usually biases the
result towards the null value, making efficacious
interventions appear less effective than they really
are. Second, pharmacoepidemiologic studies may
be biased because of differences in disease severity
between the treatment and control groups. To
minimize this possibility, we included only those
patients with severe FEV1 impairment and who
required domiciliary oxygen therapy. These strin-
gent entry criteria minimized variations in disease
severity across the comparison groups. Moreover,
we carefully collected a large amount of physiolo-
gic, co-morbid and biochemical data, which al-
lowed us to adjust for these factors in our analyses,
making it unlikely that disease severity or other
confounding issues could explain away our findings.
In this study, the causes of death are not known.
Given the frailty of these patients, it is likely that
many patients died from combined cardiopulmon-
ary causes; some may have died from lung cancer.13
Third, prescriptions for ICS were determined by
referring physicians and not randomly. Clinical
factors likely played a significant role in physician’s
decision to treat or not to treat with ICS. Despite
this, there was remarkable balance in the baselineclinical characteristics between those who were
and were not treated with ICS (Tables 2–4). Those
treated with ICS were more likely to receive
inhaled b2-agonists and oral corticosteroids, sug-
gesting that one of the determinants of ICS user
status was the severity of underlying COPD.
Our current findings are consistent with those of
Sin and Tu3 who observed in a large population-
based cohort study in Ontario, Canada, that ICS
therapy reduced COPD-related morbidity and mor-
tality in a group of elderly COPD patients. They
found that patients who received ICS within 90 days
of discharge from a hospital were 24% less likely to
experience a repeat hospitalization for COPD and
were 29% less likely to die during 1-year of follow-
up. Similar results were reported by Soriano et al.4
who demonstrated that regular use of fluticasone
was associated with increased survival of COPD
patients managed within the United Kingdom
primary care system. The third large population-
based cohort study by Sin and Man5 further
emphasized the potential of ICS to improve survival
in patients with COPD. In this study, they observed
a 25% reduction in all-cause mortality in COPD
patients who received ICS. However, there are
some dissenting studies. Suissa8 compared a time-
fixed analysis with a time-dependent analysis using
data from the Saskatchewan databases. While the
time-fixed model showed ICS to have beneficial
effects on survival, a time-dependent model did
not. Although inituitively attractive, a time-depen-
dent analysis may suffer from protopathic bias (i.e.
initiation of ICS during the follow-up period
because of increasing symptoms or disease severity
in COPD), which may bias the results toward the
null value or in some cases towards harm (when in
fact the treatment could be efficacious). A classic
example of protopathic bias related to a time-
dependent analysis was reported by the Coronary
Artery Surgery Study Investigators.14 In this study,
smoking cessation was associated with increased
risk of mortality in a time-dependent analysis.
After a careful investigation, the authors discov-
ered that many smokers had given up on smoking
just prior to their death because they had devel-
oped severe exacerbations of their underlying
cardiovascular disease. This problem was avoided
by using a time-fixed model, which rightly demon-
strated a survival benefit of smoking cessation. This
logic may also apply to the use of ICS in COPD. Blais
et al.15 have demonstrated that patients with COPD
who received ICS in the community are generally
sicker and clinically less stable than similar patients
who are not given ICS. Moreover, corticosteroids
may be used to treat their exacerbations. Thus,
exposure to ICS could be a marker of disease
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dependent model, ICS would be associated with
increased morbidity and mortality, as there would
be no way of separating the effects of these
medications from the clinical indications for which
these medications were dispensed in the first
place. Because of this possiblity, we chose in our
study to use a time-fixed model. It is possible that
during the follow-up period, some users of ICS may
have become non-users and vice versa. However,
this type of misclassification would drive the HR
toward the null value (as mentioned above),
making our estimates conservative.
Disease severity may represent one of the
important factors that may modify the effects of
ICS on survival in COPD. Anthonisen et al.16 showed
that mortality relates inversely with FEV1. More
recently, Connors et al.17 extended these findings
and showed in a prospective cohort of 1016 adult
patients with an exacerbation of COPD that survival
time after discharge was independently related to
the severity of illness and prior functional status.
Also, in our previous study on patients with chronic
respiratory insufficiency we have shown that under-
nourishment as reflected by low body mass index
and low plasma cholesterol and albumin concen-
trations were related to worse survival in such
patients.18 However, previous observational studies
(mentioned above) did not consider FEV1 or arterial
blood gases in their survival time analysis.3–5 To our
knowledge, the present study is the first to
demonstrate a significant association between the
use of ICS and the reduction in mortality rates in
patients with severe COPD and chronic respiratory
insufficiency requiring initiation of home LTOT. The
magnitude of the mortality reduction in this study
is larger than those reported previously.3,4 This may
relate to differences in the severity of COPD in the
study populations. In general, efficacious treat-
ments demonstrate the largest benefit in the
sickest patient population. For instance, in sympto-
matic congestive heart failure, angiotensin-con-
verting enzyme (ACE) inhibitors have the greatest
salutary effect on mortality in patients with the
lowest left ventricular ejection fraction (LVEF).19
For individuals with LVEF less than 23%, there was a
31% reduction in mortality with ACE inhibitors; in
contrast, in those with LVEF435%, the mortality
reduction was only 13% and did not reach statistical
significance.20 Our study population comprised
mostly of patients with very advanced disease;
whereas, other studies had a more heterogeneous
distribution of disease severity,3,4 which may
explain the disparity in the study results. Another
potential source of discrepancy is the length of
follow-up. With most efficacious pharmacologictherapies, the largest reduction in the mortality
rate occurs within the first few months of rando-
mization. For instance, in the SOLVD trial, at 6
weeks of follow-up, ACE inhibitors reduced mor-
tality by 38%; by one-year of follow-up, this was
reduced to 14%.21,22 If this phenomenon is also
present with ICS, the studies which censored the
first 90 days of follow-up because of concerns over
immortal time bias may have missed out on the
early mortality reduction of ICS and underesti-
mated the effects of ICS. Because our study did not
have a censoring period, we were able to capture
this phenomenon, if one existed.
We wish to emphasize that observational studies
such as this one are not intended to replace clinical
trials as the former are much more susceptible to
confounding than the latter. On the other hand,
observational studies reflect data from a real-life
setting and may be more generalizable than data
from clinical trials. Results are best used to extend
data from clinical trials and to generate new
hypotheses.
In conclusion, our analysis suggests that ICS may
reduce 1-year mortality rates in patients with
severe COPD and chronic respiratory insufficiency
meeting the criteria for home LTOT. These findings
add to the current clinical evidence suggesting that
ICS may play an important role in improving clinical
outcomes in COPD. Further prospective studies are
needed to confirm these findings, and to address
the mechanisms responsible for the beneficial
effects of ICS on survival in COPD.References
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